Get MindMed Updates:
TORONTO, Nov 13, 2020 /PRNewswire/ — MindMed (NEO: MMED) (OTCQB: MMEDF), a leading psychedelic medicine biotech company, has announced its third quarter financial results for the three and nine months ended September 30, 2020.
Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the disclosure documents of issuers across Canada at www.SEDAR.com.
Financial Highlights (in USD)
Total assets as of September 30, 2020 were $23.7 million, including $18.2 million in cash.
Net and comprehensive loss of $8.6 million for the three months ended Sep 30,2020, and $21.4 million for the nine months ended September 30, 2020.
MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT
MindMed Chosen to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit
MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company